Enanta Pharmaceuticals Total Liabilities

Enanta Pharmaceuticals (ENTA) currently reports a total liabilities of $200M as of March 2026. That compares with $230M in the prior-year period — down 13.7% year over year. Use the charts on this page to explore Enanta Pharmaceuticals's total liabilities history and peer comparisons.

Enanta Pharmaceuticals's total liabilities decreased from $230M to $200M — a 13.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enanta Pharmaceuticals reported $200M in total liabilities as of March 2026. That compares with $230M in the prior-year period — down 13.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.

Enanta Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $200M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTA with unrelated industries.